Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial

File TM, Goldberg L, Das A, et al. Clinical Infectious Diseases. 2019 : 1–9. DOI: 10.1093/cid/ciz090

Abstrak

Latar Belakang: Lefamulin, sebuah antibiotik pleuromotilin, aktif terhadap patogen-patogen yang sering menyebabkan pneumonia komunitas bakterial (CABP). Studi Lefamulin Evaluation Against Pneumonia (LEAP 1) merupakan percobaan noninferior global untuk mengevaluasi efikasi dan keamanan lefamulin dalam penatalaksanaan CABP.